Drugs / ISF35
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00772486 | Sep 2008 → Apr 2011 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Memgen, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00783588 | May 2007 → Sep 2008 | B-cell chronic lymphocytic leukemia | Memgen, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00779883 | Jun 2006 → Mar 2008 | B-cell chronic lymphocytic leukemia | Memgen, LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00942409 | Jun → Jul 2009 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | Januario Castro, M.D. | Terminated | No outcome recorded |
| Phase 2 | NCT00849524 | Jan → Jul 2009 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Januario Castro, M.D. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISF35 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00783588 ↗ |
| Known as | Ad-ISF35 | “Adenovirus-CD154 (Ad-ISF35)” NCT00942409 ↗ |
| Known as | Adenovirus-CD 154 | “A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma” NCT00849524 ↗1“Adenovirus-CD154 (Ad-ISF35)” NCT00942409 ↗ |
| Known as | Immune Stimulatory Factor 35 | “ISF35 is an abbreviation for Immune Stimulatory Factor 35, an offspring of technology discovered by Dr. Thomas J. Kipps, MD, PhD, Professor, Department of Medicine and Deputy...” NCT00849524 ↗1“ISF35 is an abbreviation for Immune Stimulatory Factor 35” NCT00942409 ↗ |
| Action | Activate | “binds and activates human CD40+ B lymphocytes” NCT00779883 ↗ |
| Modality | Cell therapy | “Repeated Doses of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)” NCT00772486 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion” NCT00779883 ↗ |
| Target | CD40 | “binds and activates human CD40+ B lymphocytes” NCT00779883 ↗ |